News

05/11/2022

UVA Health, Focused Ultrasound Foundation Partner to Create World’s First Focused Ultrasound Cancer Immunotherapy Center

$8 Million Investment to Fund Cutting-Edge Research, Launch Clinical Trials, Create Jobs Charlottesville, VA – UVA Health and the Charlottesville-based Focused Ultrasound Foundation today announced the launch of the Focused Ultrasound Cancer Immunotherapy Center, the world’s first center dedicated specifically to advancing a focused ultrasound and cancer immunotherapy treatment approach that could revolutionize 21st-century cancer

05/10/2022

Germany’s BfArM Approves ReAlta Life Sciences’ Phase 1b Study

Inhaled LPS Challenge Trial to Support Development of RLS-0071 in Severe Asthma RLS-0071 is ReAlta’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic ischemic encephalopathy, severe asthma, and other rare diseases Norfolk, VA, – ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing

05/04/2022

GRP named a top economic development organization in the U.S.

RICHMOND, VA – The Greater Richmond Partnership (GRP) was named among the top 20 economic development organizations in the nation according to Site Selection magazine, a national publication targeting site location professionals and corporate executives making relocation decisions. The 2022 Mac Conway Awards for Excellence in Economic Development, named in honor of Site Selection founding publisher

05/03/2022

BIO-CAT Publishes Foundational Study of Digestive Enzyme Function

TROY, Va.,/PRNewswire/ — A clinical trial designed by BIO-CAT, Inc – a biotech company specializing in enzyme development – studied the use of enzymes to improve digestion in an in vitro model of aging. The results showed that a multi-component supplemental enzyme blend (microbial proteases, lipase, amylase, and glucoamylase) effectively released nutrients from a balanced meal better

05/03/2022

AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases

CHARLOTTESVILLE, Va., – AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma. Revealed in the peer-reviewed journal Science Advances, the paper details AMPEL’s breakthrough machine learning approach to characterize disease activity from gene expression data obtained

04/27/2022

Richmond medical technology company raises $1M

Richmond medical technology company Tympanogen Inc. has raised $1 million in fresh funding, according to a Securities and Exchange Commission filing. Tympanogen raised the money from 12 investors and said it is seeking to raise up to $2.5 million through debt and other options, according to the March filing. The round includes participation from Williamsburg’s ShockVentures